Payment overview · 2025
General Payments
$571.76
16 reported records · 8 companies
Healthcare provider profile · identity verified
William B Lee, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARION, AL · NPI 1770019515
Verified facts
What the public records show
CMS Open Payments records show William B Lee, MD received $571.76 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $199.16 | 34.8% | 3 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $169.00 | 29.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $65.37 | 11.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.11 | 6.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.50 | 6.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.70 | 5.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.66 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.26 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $571.76 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $169.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.94 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $65.37 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.57 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.70 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 372 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 368 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 327 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 66 |
| Furosemide | Furosemide | 249 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 79 |
| Potassium Chloride | Potassium Chloride | 238 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 199 | 35 |
| Losartan Potassium | Losartan Potassium | 193 | 46 |
| Eliquis | Apixaban | 173 | 27 |
| Famotidine | Famotidine | 158 | 44 |
| Tramadol Hcl | Tramadol Hcl | 142 | 37 |
| Mirtazapine | Mirtazapine | 137 | 33 |
| Pregabalin | Pregabalin | 135 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 54 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | 27 |
| Divalproex Sodium | Divalproex Sodium | 125 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 42 |
| Allopurinol | Allopurinol | 113 | 26 |
| Clonazepam | Clonazepam | 111 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 26 |
| Metformin Hcl Er | Metformin Hcl | 99 | 28 |
| Metformin Hcl | Metformin Hcl | 98 | 29 |
| Alprazolam | Alprazolam | 93 | 22 |
| Lorazepam | Lorazepam | 93 | 25 |
| Naproxen | Naproxen | 87 | 29 |
| Colchicine | Colchicine | 84 | 25 |
| Prednisone | Prednisone | 84 | 47 |
| Trazodone Hcl | Trazodone Hcl | 84 | 17 |
| Meloxicam | Meloxicam | 82 | 35 |
| Carvedilol | Carvedilol | 81 | 22 |
| Simvastatin | Simvastatin | 80 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 20 |
| Buspirone Hcl | Buspirone Hcl | 76 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 23 |
| Omeprazole | Omeprazole | 76 | 25 |
| Ozempic | Semaglutide | 75 | 13 |
| Memantine Hcl | Memantine Hcl | 72 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 17 |
| Sertraline Hcl | Sertraline Hcl | 66 | 15 |
| Methylprednisolone | Methylprednisolone | 61 | 44 |
| Clonidine Hcl | Clonidine Hcl | 60 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 15 |
| Trulicity | Dulaglutide | 58 | 13 |
| Lisinopril | Lisinopril | 55 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 53 | 15 |
| Fentanyl | Fentanyl | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 51 | 16 |
| Entresto | Sacubitril/Valsartan | 51 | suppressed |
| Fluconazole | Fluconazole | 50 | 36 |
| Farxiga | Dapagliflozin Propanediol | 49 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 31 |
| Telmisartan | Telmisartan | 48 | 13 |
| Linzess | Linaclotide | 47 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 47 | suppressed |
| Mupirocin | Mupirocin | 46 | 32 |
| Spironolactone | Spironolactone | 45 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 16 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 37 |
| Haloperidol | Haloperidol | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 36 |
| Ibuprofen | Ibuprofen | 39 | 22 |
| Levetiracetam | Levetiracetam | 39 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Nystatin | Nystatin | 37 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 23 |
| Cefadroxil | Cefadroxil | 34 | 30 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 33 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 25 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Ingrezza | Valbenazine Tosylate | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Ramelteon | Ramelteon | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 16 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Humira | Adalimumab | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $571.76 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, Ozempic, REXULTI, Zunveyl | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error